Skip to content
Homepage
Author:
Mapi Pharma
Posted Date:
June 1, 2026
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
Mapi Pharma
June 1, 2026
Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables
Mapi Pharma
May 4, 2026
Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026
Mapi Pharma
April 16, 2026
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
Mapi Pharma
February 19, 2026
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
Mapi Pharma
February 3, 2026
